Pharmacodynamics of finafloxacin, ciprofloxacin, and levofloxacin in serum and urine against TEM- and SHV-type extended-spectrum-β-lactamase-producing enterobacteriaceae isolates from patients with urinary tract infections

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Dalhoff, A ^a   Schubert, S ^a   Vente, A ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b MerLion Pharmaceuticals GmbH   (Germany)

Author keywords

ESBL; Finafloxacin; Fluoroquinolones; Pharmacodynamics; Urine

Indexed keywords

CIPROFLOXACIN; FINAFLOXACIN; LEVOFLOXACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARTMENT MODEL; CONTROLLED STUDY; CULTURE MEDIUM; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SERUM; URINALYSIS; URINARY TRACT INFECTION; BLOOD; DRUG EFFECTS; ESCHERICHIA COLI; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; URINE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BLOOD; CIPROFLOXACIN; ESCHERICHIA COLI; FLUOROQUINOLONES; HUMANS; KLEBSIELLA PNEUMONIAE; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS; URINE;

EID: 85018181384     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02446-16     Document Type: Article

References (74)

1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. 2015. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 13:269-284. https://doi.org/10.1038/nrmicro3432.
2. Ronald A. 2002. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 113(Suppl 1A):14S-19S. https://doi.org/10.1016/S0002-9343(02)01055-0.
3. Kahlmeter G. 2003. An international survey of the antimicrobial susceptibility of pathogens from acute uncomplicated urinary tract infections: the ECO. SENS project. J Antimicrob Chemother 51:69-76. https://doi.org/10.1093/jac/dkg028.
4. Kahlmeter G, Poulsen HO. 2012. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 39:45-51. https://doi.org/10.1016/j.ijantimicag.2011.09.013.
5. Kahlmeter G, Ahman J, Matuschek E. 2015. Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect Dis Ther 4:417-423. https://doi.org/10.1007/s40121-015-0095-5.
6. Heytens S, Boelens J, Claeys G, De Sutter A, Christiaens T. 2017. Uropathogen distribution and antimicrobial susceptibility in uncomplicated cystitis in Belgium, a high antibiotics prescribing country: 20-year surveillance. Eur J Clin Microbiol Infect Dis 36:105-113. https://doi.org/10.1007/s10096-016-2776-8.
7. Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, Williamson DA, Paterson DL. 2015. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 12:570-584. https://doi.org/10.1038/nrurol.2015.199.
8. Antony SJ. 2011. The changing epidemiology of extended spectrum beta-lactamases (ESBL) infections of urinary tract focusing on clinical resistance and therapeutic options, clinical management and therapeutic options, p 19-32. In Nikibakhsh A (ed), Clinical management of complicated urinary tract infection. InTech, Shanghai, China. https://doi.org/10.5772/21909.
9. Arana DM, Rubio M, Alos JI. 4 April 2016. Evolution of antibiotic multiresistance in Escherichia coli and Klebsiella pneumoniae isolates from urinary tract infections: a 12-year analysis (2003-2014). Enferm Infecc Microbiol Clin https://doi.org/10.1016/j.eimc.2016.02.018.
10. Pitout JDD, Nordmann P, Laupland KB, Poirel L. 2005. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52-59. https://doi.org/10.1093/jac/dki166.
11. Livermore D. 2007. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 59:165-174. https://doi.org/10.1093/jac/dkl483.
12. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. 2015. Antibiotic resistance and extended spectrum beta-lactamases: types, epidemiology and treatment. Saudi J Biol Sci 22:90-101. https://doi.org/10.1016/j.sjbs.2014.08.002.
13. Sullivan R, Schaus D, John M, Delport JA. 2015. Extended spectrum beta-lactamases: a minireview of clinical relevant groups. J Med Microbiol Diagn 4:203. https://doi.org/10.4172/2161-0703.1000203.
14. Rodríguez-Baño J, Navarro MD, Romero L, Martínez-Martínez L, Muniain MA, Perea EJ, Pérez-Cano R, Pascual A. 2004. Epidemiology and clinical features of infections caused by extended-spectrum-β-lactamaseproducing Escherichia coli in nonhospitalized patients. J Clin Microbiol 42:1089-1094. https://doi.org/10.1128/JCM.42.3.1089-1094.2004.
15. Lagacé-Wiens PRS, Nichol KA, Nicolle LE, De Corby MR, McCracken M, Alfa MJ, Mulvey MR, Zhanel GG. 2007. ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible, ESBL-producing Escherichia coli urinary isolates in Manitoba. Can J Infect Dis Med Microbiol 18:133-137.
16. Machado E, Cantón R, Baquero F, Galán JC, Rollán A, Peixe L, Coque TM. 2005. Integron content of extended-spectrum-β-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Antimicrob Agents Chemother 49:1823-1829. https://doi.org/10.1128/AAC.49.5.1823-1829.2005.
17. Machado E, Ferreira J, Novais Â, Peixe L, Cantón R, Baquero F, Coque TM. 2007. Preservation of integron types among Enterobacteriaceae producing extended-spectrum β-lactamases in a Spanish hospital over a 15-year period (1988 to 2003). Antimicrob Agents Chemother 51:2201-2204. https://doi.org/10.1128/AAC.01389-06.
18. Machado E, Coque TM, Cantón R, Sousa JC, Peixe L. 2013. Commensal Enterobacteriaceae as reservoirs of extended-spectrum β-lactamases, integrons, and sul genes in Portugal. Front Microbiol 4:80. https://doi.org/10.3389/fmicb.2013.00080.
19. Paterson DL, Mulazimoglu L, Casellas JM, Ko WC, Goossens H, von Gottberg A, Mohapatra S, Trenholme GM, Klugman KP, McCormack JG, Yu VL. 2000. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 30:473-478. https://doi.org/10.1086/313719.
20. Zurfluh K, Abgottspon H, Hächler H, Nuesch-Inderbinen M, Stephan R. 2014. Quinolone resistance mechanisms among extended-spectrum beta-lactamase (ESBL) producing Escherichia coli isolated from rivers and lakes in Switzerland. PLoS One 9(4):e95864. https://doi.org/10.1371/journal.pone.0095864.
21. Bajaj P, Kanaujia PK, Singh NS, Sharma S, Kumar S, Virdi JS. 2016. Quinolone co-resistance in ESBL- or AmpC-producing Escherichia coli from an Indian urban aquatic environment and their public health implications. Environ Sci Pollut Res 23:1954-1959. https://doi.org/10.1007/s11356-015-5609-x.
22. Sorlozano A, Gutierrez J, Jimenez A, de Dios Luna J, Martínez JL. 2007. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-β-lactamase-producing Escherichia coli isolates. J Clin Microbiol 45:2740-2742. https://doi.org/10.1128/JCM.01093-07.
23. Schmiedel J, Falgenhauer L, Domann E, Bauerfeind R, Prenger-Berninghoff E, Imirzalioglu C, Chakraborty T. 2014. Multiresistant extended-spectrum β-lactamase-producing Enterobacteriaceae from humans, companion animals and horses in central Hesse, Germany. BMC Microbiol 14:187. https://doi.org/10.1186/1471-2180-14-187.
24. Donati V, Feltrin F, Hendriksen RS, Svendsen CA, Cordaro G, Garcia-Fernandez A, Lorenzetti S, Lorenzetti R, Battisti A, Franco A. 2014. Extended-spectrum-beta-lactamases, AmpC beta-lactamases and plasmid mediated quinolone resistance in Klebsiella spp. from companion animals in Italy. PLoS One 9(3):e90564. https://doi.org/10.1371/journal.pone.0090564.
25. Sohn KM, Kang CI, Joo EJ, Ha YE, Chung DR, Peck KR, Lee NY, Song JH. 2011. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Proteus mirabilis bacteremia. Korean J Int Med 26:89-93. https://doi.org/10.3904/kjim.2011.26.1.89.
26. Cattoir V, Poirel L, Rotimi V, Soussy CJ, Nordmann P. 2007. Multiplex PCR for detection of plasmid-mediated quinolone resistance qnr genes in ESBL-producing enterobacterial isolates. J Antimicrob Chemother 60: 394-397. https://doi.org/10.1093/jac/dkm204.
27. Huang S, Dai W, Sun S, Zhang X, Zhang L. 2012. Prevalence of plasmidmediated quinolone resistance and aminoglycoside resistance determinants among carbapenem non-susceptible Enterobacter cloacae. PLoS One 7(10):e47636. https://doi.org/10.1371/journal.pone.0047636.
28. Barguigua A, El Otmani F, Talmi M, Bourjilat F, Haouzane F, Zerouali K, Timinouni M. 2011. Characterization of extended-spectrum β-lactamaseproducing Escherichia coli and Klebsiella pneumoniae isolates from the community in Morocco. J Med Microbiol 60:1344-1352. https://doi.org/10.1099/jmm.0.032482-0.
29. Barguigua A, El Otmani F, Talmi M, Reguig A, Jamali L, Zerouali K, Timinouni M. 2013. Prevalence and genotypic analysis of plasmidmediated β-lactamases among urinary Klebsiella pneumoniae isolates in Moroccan community. J Antibiot 66:11-16. https://doi.org/10.1038/ja.2012.91.
30. Younes A, Hamouda A, Dave J, Amyes SGB. 2011. Prevalence of transferable blaCTX-M-15 from hospital- and community-acquired Klebsiella pneumoniae isolates in Scotland. J Antimicrob Chemother 66:313-318. https://doi.org/10.1093/jac/dkq453.
31. Pakzad I, Ghafourian S, Taherikalani M, Abtahi H, Rahbar M, Mansory Jamshidi N. 2011. Qnr prevalence in extended spectrum beta-lactamases (ESBLs) and none-ESBLs producing Escherichia coli isolated from urinary tract infections in central of Iran. Iran J Basic Med Sci 14:458-464.
32. DHA-1 genes in clinical strain of Morganella morganii recovered from a Tunisian intensive care unit. Indian J Med Microbiol 30:437-441. https://doi.org/10.4103/0255-0857.103765.
33. Richter SN, Frasson I, Bergo C, Manganelli R, Cavallaro A, Palu G. 2010. Characterisation of qnr plasmid-mediated quinolone resistance in Enterobacteriaceae from Italy: association of the qnrB19 allele with the integron element ISCR1 in Escherichia coli. Int J Antimicrob Agents 35: 578-583. https://doi.org/10.1016/j.ijantimicag.2010.02.015.
34. Dahmen S, Poirel L, Mansour W, Bouallegue O, Nordmann P. 2010. Prevalence of plasmid-mediated quinolone resistance determinants in Enterobacteriaceae from Tunisia. Clin Microbiol Infect 16:1019-1023. https://doi.org/10.1111/j.1469-0691.2009.03010.x.
35. Bado I, Cordeiro NF, Robino L, Garcia-Fulueiras V, Seija V, Bazet C, Gutkind G. 2010. Detection of class 1 and 2 integrons, extendedspectrum β-lactamases and qnr alleles in enterobacterial isolates from the digestive tract of intensive care unit inpatients. Int J Antimicrob Agents 36:453-458. https://doi.org/10.1016/j.ijantimicag.2010.06.042.
36. Lavilla S, González-López JJ, Sabaté M, García-Fernández A, Larrosa MN, Bartolomé RM, Carattoli A, Prats G. 2008. Prevalence of qnr genes among extended-spectrum beta-lactamase-producing enterobacterial isolates in Barcelona, Spain. J Antimicrob Chemother 6:291-295.
37. Dalhoff A. 2012. Global fluoroquinolone resistance: epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis 2012:976273. https://doi.org/10.1155/2012/976273.
38. Grabe M, Bartoletti R, Bjerklund-Johansen TE, Cai T, Cek HM, Köves B, Naber KG, Pickard RS, Tenke P, Wagenlehner F, Wullt B. 2015. Guidelines on urological infections. European Association of Urology, Arnhem, Netherlands. http://uroweb.org/wp-content/uploads/19-Urological-infections-LR2.pdf.
39. Gupta K, Naber K, Stamm W. 2003. Treatment of urinary tract infections, p 159-170. In Hooper DC, Rubinstein E (ed), Quinolone antibacterial agents, 3rd ed. ASM Press, Washington, DC.
40. Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. 2001. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolones exposure. J Antimicrob Chemother 48:375-381. https://doi.org/10.1093/jac/48.3.375.
41. Dalhoff A, Schubert S. 2010. Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones. Int J Antimicrob Agents 36:216-221. https://doi.org/10.1016/j.ijantimicag.2010.04.014.
42. Paterson DL. 2004. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 38(Suppl 4):341-345. https://doi.org/10.1086/382690.
43. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. 2011. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52:e103-e120. https://doi.org/10.1093/cid/ciq257.
44. Stubbings W, Leow P, Yong GC, Goh F, Körber-Irrgang B, Kresken M, Endermann R, Labischinski H. 2011. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob Agents Chemother 55:4394-4397. https://doi.org/10.1128/AAC.00833-10.
45. Lemaire S, van Bambeke F, Tulkens PM. 2011. Activity of finafloxacin, a novel fluoroquinolone with increased activity at acid pH, towards extracellular and intracellular Staphylococcus aureus, Listeria monocytogenes and Legionella pneumophila. Int J Antimicrob Agents 38:52-59. https://doi.org/10.1016/j.ijantimicag.2011.03.002.
46. Idelevich EA, Kriegeskorte A, Stubbings W, Kahl BC, Peters G, Becker K. 2011. Comparative in vitro activity of finafloxacin against staphylococci displaying normal and small colony variant phenotypes. J Antimicrob Chemother 66:2809-2813. https://doi.org/10.1093/jac/dkr393.
47. Patel H, Andresen A, Vente A, Heilmann HD, Stubbings W, Seiberling M, Lopez-Lazaro L, Pokorny R, Labischinski H. 2011. Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers. Antimicrob Agents Chemother 55:4386-4393. https://doi.org/10.1128/AAC.00832-10.
48. Wagenlehner FME, Wagenlehner CM, Blenk B, Blenk H, Schubert S, Dalhoff A, Naber KG. 2011. Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose. Chemotherapy 57:97-107. https://doi.org/10.1159/000321028.
49. Dalhoff A, Stubbings W, Schubert S. 2011. Comparative in vitro activities of the novel antibacterial finafloxacin against selected Gram-positive and Gram-negative bacteria tested in Mueller-Hinton broth and synthetic urine. Antimicrob Agents Chemother 55:1814-1818. https://doi.org/10.1128/AAC.00886-10.
50. Wagenlehner F, Nowicki M, Bentley C, Lückermann M, Wohlert S, Fischer C, Vente A, Naber K, Dalhoff A. 2015. Safety and efficacy of finafloxacin versus ciprofloxacin in the treatment of hospitalized patients with complicated urinary tract infections and pyelonephritis determined in a phase 2 clinical study, abstr L-1251. 55th Intersci Conf Antimicrob Agents Chemother, San Diego, CA.
51. European Agency for the Evaluation of Medicinal Products. 2010. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/QWP/1401/98. European Agency for the Evaluation of Medicinal Products, London, United Kingdom.
52. Bryskier A. 2005. Fluoroquinolones, p 668-788. In Bryskier A (ed), Antimicrobial agents. ASM Press, Washington, DC.
53. Wohlert S, Jaetsch T, Gallenkamp B, Knops HJ, Lui N, Preiss M, Haebich D, Labischinski H. 2008. New fluoroquinolone finafloxacin HCl: route of synthesis, physicochemical characteristics and activity under neutral and acidic conditions, poster F1-2036. Abstr 48th Intersci Conf Antimicrob Agents Chemother (ICAAC)-Infect Dis Soc Am (IDSA) 46th Annu Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
54. Wetzstein HG, Hallenbach W. 2011. Tuning of antibacterial activity of a cyclopropyl fluoroquinolone by variation of the substituent at position C-8. J Antimicrob Chemother 66:2801-2808. https://doi.org/10.1093/jac/dkr372.
55. Körber-Irrgang B, Kresken M, Wetzstein HG. 2009. pH-dependence of the activity of pradofloxacin structural analogs against Escherichia coli and Staphylococcus aureus, abstr E-1967/44. 49th Intersci Conf Antimicrob Agents Chemother, San Francisco, CA.
56. Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P. 2010. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance. J Antimicrob Chemother 65:2530-2533. https://doi.org/10.1093/jac/dkq375.
57. Randall LB, Georgi E, Genzel GH, Schweizer HP. 30 December 2016. Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance. J Antimicrob Chemother https://doi.org/10.1093/jac/dkw529.
58. Bartoletti R, Cai T, Perletti G, Wagenlehner F, Bjerklund Johansen TE. 2015. Finafloxacin for the treatment of urinary tract infections. Expert Opin Invest Drugs 24:957-963. https://doi.org/10.1517/13543784.2015.1052401.
59. Griffith DP, Musher DM, Itin C. 1976. Urease. The primary cause of infection-induced urinary stones. Invest Urol 13:346-350.
60. Wagenlehner FME. 2012. Do we need PK/PD in the treatment of urogenital infections? Chemotherapy 1:e105. https://doi.org/10.4172/2167-7700.1000e105.
61. Frimodt-Møller N. 2002. Correlation between pharmacokinetic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19:546-553. https://doi.org/10.1016/S0924-8579(02)00105-X.
62. Meagher AK, Forrest A, Dalhoff A, Stass H, Schentag JJ. 2004. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother 48:2061-2068. https://doi.org/10.1128/AAC.48.6.2061-2068.2004.
63. Schuck EL, Dalhoff A, Stass H, Derendorf H. 2005. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form. Infection 33(Suppl 2):S22-S28. https://doi.org/10.1007/s15010-005-8204-0.
64. Frei CR, Wiederhold NP, Burgess DS. 2008. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61: 621-628. https://doi.org/10.1093/jac/dkm536.
65. So W, Crandon LJ, Nicolau DP. 2015. Effects of urine matrix and pH on the potency of delafloxacin and ciprofloxacin against urogenic Escherichia coli and Klebsiella pneumoniae. J Urol 194:563-570. https://doi.org/10.1016/j.juro.2015.01.094.
66. Martín-Gutiérrez G, Rodriguez-Betran J, Rodriguez-Martinez J, Costas C, Aznar J, Pascual A, Blazquez J. 2016. Urinary tract physiological conditions promote ciprofloxacin resistance in low-level-quinolone-resistant Escherichia coli. Antimicrob Agents Chemother 60:4252-4258. https://doi.org/10.1128/AAC.00602-16.
67. Grasso S, Meinardi G, de Carneri I, Tamassia V. 1978. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother 13:570-576. https://doi.org/10.1128/AAC.13.4.570.
68. Dudley MN. 2003. Pharmacokinetics of fluoroquinolones, p 115-132. In Hooper DC, Rubinstein E (ed), Quinolone antibacterial agents, 3rd ed. ASM Press, Washington, DC.
69. Bergan T, Dalhoff A, Rohwedder R. 1988. Pharmacokinetics of ciprofloxacin. Infection 16(Suppl 1):S3-S13. https://doi.org/10.1016/S0163-4453 (88)96029-X.
70. Wagenlehner FME, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Dalhoff A, Naber K. 2006. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose. Int J Antimicrob Agents 27:7-14. https://doi.org/10.1016/j.ijantimicag.2005.09.014.
71. Wagenlehner FME, Kinzig-Schippers M, Tischmeyer U, Wagenlehner C, Sörgel F, Naber K. 2006. Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. Antimicrob Agents Chemother 50:3947-3949. https://doi.org/10.1128/AAC.00477-06.
72. Chien SC, Wong FA, Fowler CL, Callery-D'Amico SV, Williams RR, Nyak R, Chow AT. 1998. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 42: 885-888.
73. Tisdale JE, Pasko MT, Mylotte JM. 1989. Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the curve. Antimicrob Agents Chemother 33:1500-1505. https://doi.org/10.1128/AAC.33.9.1500.
74. Dalhoff A. 1995. Pharmacodynamics of quinolones. Drugs 49(Suppl 2): S197-S199.